Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.

Hayoung ChoiJae-Kyeong LeeHyung-Joo OhMin-Seok KimBo Gun KhoCheol-Kyu Park In Jae Oh Young-Chul Kim

Published in: Thoracic cancer (2021)

The efficacy of afatinib was similar to that identified in the global data without unexpected adverse events. Survival analyses support the currently approved dose of afatinib as first-line treatment for NSCLC.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
small cell lung cancer
tyrosine kinase
electronic health record
combination therapy
machine learning
drug administration
deep learning